Adlai Nortye Ltd. Sponsored ADR (ANL) vs Cullinan Therapeutics, Inc. (CGEM)

Adlai Nortye Ltd. Sponsored ADR and Cullinan Therapeutics, Inc. are both Biotechnology companies. Adlai Nortye Ltd. Sponsored ADR and Cullinan Therapeutics, Inc. are of similar size ($992.4M and $929.7M). Across the 7 metrics below, Adlai Nortye Ltd. Sponsored ADR leads on 6 and Cullinan Therapeutics, Inc. on 1.

Valuation

Metric ANL CGEM Biotechnology median
P/E — n/m 7.88
P/S — n/m 11.47
P/B n/m 2.82 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m n/m 10.73
Earnings yield — (21.05%) (28.84%)
Free cash flow yield 0.00% (17.59%) (23.03%)

Profitability

Metric ANL CGEM Biotechnology median
Gross margin — — 65.16%
Operating margin — 0.00% 0.00%
Net margin — 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (50.30%) (57.72%)
Return on assets 0.00% (46.30%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ANL CGEM Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 31.48% (20.86%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ANL CGEM Biotechnology median
Debt to equity 0.12 0.00 0.00
Current ratio 9.55 8.42 4.73
Net debt to EBITDA (0.05) 1.57 0.96

Dividend

Metric ANL CGEM Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric ANL CGEM Biotechnology median
Market cap 929.70m 992.35m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack